Cargando…
Correlation of Decreased Serum Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide Levels With Non-motor Symptoms in Patients With Parkinson’s Disease
Objective: Pituitary adenylate-cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) are two neuropeptides that exhibit anti-inflammatory and neuroprotective properties, modulating the production of cytokines and chemokines, and the behavior of immune cells. However, the rel...
Autores principales: | Hu, Shiyu, Huang, Shen, Ma, Jianjun, Li, Dongsheng, Zhao, Zhenxiang, Zheng, Jinhua, Li, Mingjian, Wang, Zhidong, Sun, Wenhua, Shi, Xiaoxue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457255/ https://www.ncbi.nlm.nih.gov/pubmed/34566619 http://dx.doi.org/10.3389/fnagi.2021.689939 |
Ejemplares similares
-
Retinoprotective Effects of TAT-Bound Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase Activating Polypeptide
por: Atlasz, Tamas, et al.
Publicado: (2018) -
Pituitary adenylate cyclase activating polypeptide and migraine
por: Zagami, Alessandro S, et al.
Publicado: (2014) -
Pituitary Adenylate Cyclase-Activating Polypeptide in Learning and Memory
por: Gilmartin, Marieke R., et al.
Publicado: (2021) -
Examination of pituitary adenylate cyclase-activating polypeptide in Parkinson’s disease focusing on correlations with motor symptoms
por: Pham, Daniel, et al.
Publicado: (2022) -
Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide Against Cognitive Decline in Neurodegenerative Diseases
por: Solés-Tarrés, Irene, et al.
Publicado: (2020)